Federal Register of Legislation - Australian Government

Primary content

PB 90 of 2019 Determinations/Health as made
This instrument amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine the originator brand of a new pharmaceutical item of an existing Pharmaceutical Benefits Scheme (PBS) listed drug on the F2 formulary on 1 November 2019. It also determines an additional originator brand of an existing PBS listed drug on the F2 formulary.
Administered by: Health
Registered 31 Oct 2019
Tabling HistoryDate
Tabled Senate11-Nov-2019

PB 90 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 8)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated       30 October 2019

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 8).

(2)     This Determination may also be cited as PB 90 of 2019.

2              Commencement

                This Determination commences on 1 November 2019.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).


Schedule 1     Amendments

(section 3)

[1]                   Schedule 1, (table item 74A)

Repeal the item:

74A

Enoxaparin

Clexane

 

 

Substitute:

74A

Enoxaparin

Clexane

Clexane Safety-Lock

 

 

[2]                   Schedule 1, (table item 157A)

Repeal the item:

157A

Naloxone

Naloxone Hydrochloride (DBL)

 

 

Substitute:

157A

Naloxone

Naloxone Hydrochloride (DBL)

Injection

 

 

 

Nyxoid

Nasal